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Context: The last decades have provided insights into vitamin D physiology linked to glucose homeostasis.
Uncertainties remain in obesity due to its intrinsic effects on vitamin D and glucose tolerance.
Objectives: To assess the relationship between vitamin D and glucose abnormalities in severely obese individuals
previously unknown to suffer from abnormal glucose metabolism.
Setting: Tertiary care centre.
Patients: 524 obese patients (50.3 ± 14.9 yrs; BMI, 47.7 ± 7.3 kg/m2) screened by OGTT, HbA1c and the lipid profile.
Vitamin D status was assessed by 25(OH)D3, PTH and electrolyte levels. 25(OH)D3 deficiency/insufficiency were set at
20 and 30 ng/ml, respectively. All comparative and regression analyses were controlled for age, BMI and gender.
Results: The prevalence of vitamin D deficiency/insufficiency and secondary hyperparathyroidism were 95% and
50.8%, respectively. Normal glucose tolerance (NGT), impaired fasting glucose (IFG) or impaired glucose tolerance
(IGT), and type 2 diabetes mellitus (T2DM) were found in 37.8%, 40.5% and 21.7% of cases, respectively. Large
variations in metabolic parameters were seen across categories of vitamin D status, but the only significant
differences were found for C-peptide, tryglicerides, LDL- and HDL-cholesterol levels (p < 0.05 for all). The prevalence
of vitamin D deficiency was documented to be slightly but significantly more frequent in glucose-intolerant patients
(IFG + IGT + T2DM) compared to the -normotolerant counterpart (87% vs. 80%, p < 0.05). In partial correlation
analyses, there was no association between vitamin D levels and glucose-related markers but for HbA1c (r = −0.091,
p < 0.05), and both basal and OGTT-stimulated insulin levels (r = 0.097 and r = 0.099; p < 0.05 for all). Vitamin D levels
were also correlated to HDL-cholesterol (r = 0.13, p = 0.002). Multivariate regression analysis inclusive of vitamin D,
age, BMI, gender and fat mass as independent variables, showed that vitamin D was capable of predicting HbA1c
levels (β = −0.101, p < 0.05).
Conclusions: Given the inherent effect of obesity on vitamin D and glucose homeostasis, current data suggest a
potential independent role for vitamin D in the regulation of glucose metabolism in a setting of obese patients
previously unknown to harbour glucose metabolism abnormalities.* Correspondence: marzullo@med.unipmn.it
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Vitamin D is a secosteroid hormone, with an established
role in bone homeostasis. Its di-hydroxylated active me-
tabolite [1], 1,25(OH)2D3, binds the vitamin D nuclear re-
ceptor (VDR) and translocates to the nucleus to regulate
gene expression [2]. Being the VDR located in several cells
and tissues, a number of new hypothetical functions have
been postulated to expand vitamin D role beyond its
ability to regulate calcium homeostasis. As such, VDR has
been found to affect 229 human genes [3], and in vivo and
in vitro studies have increasingly linked vitamin D homeo-
stasis to cardiovascular, autoimmune, tumoral, pulmonary
and neurological diseases [4-7].
Assessment of vitamin D status relies on plasma meas-
urement of its circulating metabolite, 25-hydroxyvitamin D
(25(OH)D3), which is more stable, has a longer half-life and
reflects vitamin D storage more accurately than the active
form [8]. Although no definitive consensus currently exists
on the lowest 25(OH)D3 levels of normalcy, the 25(OH)D3
threshold of 30 ng/ml (75 nmol/l) is deemed as adequate
for fracture prevention in the general older population
[9-11], while the 20 ng/ml cutoff limit has been alter-
natively suggested to differentiate populations at true
risk for the effects of vitamin D deficiency [12]. Cohort
studies showed that vitamin D inadequacy occurs in
approximately 36% of otherwise healthy young adults and
up to 57% of inpatients, with even higher rates applying to
European populations [13,14].
Causal factors of vitamin D deficiency include aging
[15], longer life expectancy [16], lifestyle habits [17],
and metabolic disorders [18]. An increased proportion
of body fat as well as obesity have been documented to
decrease bioavailability of cholecalciferol [19-21], due to
its preferential accumulation in the adipose tissue [22].
Especially, a deranged vitamin D status may reflect an
increased risk of type 2 diabetes mellitus (T2DM) in
the general population [23]. While it is not completely
clarified how vitamin D acts on glucose metabolism,
postulated mechanisms include direct effects on insu-
lin synthesis and release mediated by the VDR [24],
and negative effects on insulin sensitivity elicited by
secondary elevation of PTH levels [25]. As vitamin D
upregulates lipoprotein lipase (LPL), this latter has been
suggested to act as a potential link between vitamin D
and glucose metabolism [26]. Nevertheless, the poten-
tial effects of vitamin D status on insulin sensitivity are
debated, as the correlation between vitamin D and re-
sponse to insulin has been found direct by some studies
[27] and modestly significant by others [28]. Recently,
Muscogiuri and colleagues found that the correlation
between low vitamin D levels and insulin resistance
could be influenced by obesity, which was demonstrated
to be the only predictor of low vitamin D levels [29] by
multivariate analysis.In this study, we aimed at exploring the relationship
between vitamin D status and glucose homeostasis follow-
ing screening for T2DM in a population of obese patients
previously undiagnosed with abnormalities of glucose
metabolism. To this purpose, our aims were: to subject
obese patients to screening of glucose tolerance and
insulin resistance by the OGTT and HbA1c levels, and
evaluation of the lipid profile; to assess the prevalence
of hypovitaminosis D and secondary hyperparathyroidism
in severe obesity; to examine the relationship linking
low vitamin D concentrations to glucose intolerance,
T2DM and lipid markers after correction for key vari-
ables linked to these parameters; to identify a predictive
role of vitamin D concentrations on glucose and lipid
metabolism in this cohort.
Material and methods
We performed a single centre study in severely obese
patients referring to the Istituto Auxologico Italiano
(Verbania, Italy) for work-up and rehabilitation of their
obese status. Data presented herein are part of a larger
screening study on the prevalence of previously undiag-
nosed glucose intolerance or incident T2DM in obesity
(Type 2 diabetes mellitus Of New Diagnosis in Obesity,
TONDO). More specifically, the TONDO study was
designed to investigate the relationship between newly
diagnosed glucose abnormalities and biochemical or
functional markers of organ damage in subjects with
uncomplicated and complicated obesity, with BMIs
spanning from 35 to 70 kg/m2. Current data refer to an
ad interim analysis on the relationship between vita-
min D status and glucose metabolism. Approval from
the Ethic Committee was obtained prior to the begin-
ning of the study, and all patients signed the informed
consent before enrollment into the study.
The current analysis included 524 consecutive cau-
casian subjects affected with grade II and III obesity
(BMI ≥35 kg/m2), aged ≥ 18 years. Exclusion criteria were
as follows: previously known T1DM and untreated or
treated T2DM; hormone treatments including cortico-
steroids; any therapy capable of influencing calcium
metabolism; previous or current vitamin D treatment;
comorbidities affecting vitamin D metabolism, such as
chronic kidney disease, liver cirrhosis, gastroentero-
pancreatic disturbances, autoimmune disorders, primary
hyperparathyroidism.
Upon enrollment, data were resumed as follows: height,
weight, BMI (kg/m2), waist and hip circumferences,
waist-to-hip ratio (WHR), personal and family history,
ongoing therapies, body composition. Routine laboratory
data included levels of 25(OH)D3, PTH, calcium and phos-
phorus, and C-reactive protein. Glucose metabolism was
assessed by fasting plasma glucose, insulin and C-peptide
levels; oral glucose tolerance test (OGTT) for glucose and
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analysis included total-cholesterol (t-CHO), high density
lipoprotein-cholesterol (HDL-CHO), low density lipopro-
tein -cholesterol (LDL-CHO) and triglycerides levels.
ADA recommendations [30] were used for the definition
of glucose metabolism and T2DM, as follows: normal fast-
ing plasma glucose (FPG) if <100 mg/dl (5.6 mmol/l); im-
paired FPG (IFG) if FPG was 100–125 mg/dl (6.9 mmol/l);
impaired glucose tolerance (IGT) if 2-h post-OGTT plasma
glucose was 140–199 mg/dl (7.8-11.0 mmol/l); T2DM
if FPG was ≥126 mg/dl (≥7 mmol/l) on two days apart,
or if 2-h post-OGTT plasma glucose was ≥200 mg/dl
(≥11.1 mmol/l). HbA1c values of 5.7 and 6.5% were
considered as the threshold of normal glucose metabolism
and T2DM, respectively. Insulin resistance was calculated
by the homeostatic model of insulin resistance (HOMA-IR)
as fasting insulin (μU/m) × [fasting PG (mmol/l)/22.5]. Vita-
min D status was defined according to current guidelines
[11] as: deficiency, 25(OH)D3 < 20 ng/ml; insufficiency, 25
(OH)D3 20–29 ng/ml; adequacy, 25(OH)D3 ≥ 30 ng/ml.
Waist was measured as halfway between the costal
edge and the crista. Hip was measured as the greatest
circumference around the nates.
Body composition was evaluated according to percent-
age of fat and fat-free mass. Fat mass (FM), fat-free mass
(FFM), total body water, and extracellular water (ECW)
were determined by bioelectrical impedance analysis
(BIA 101/S; Akern, Florence, Italy). Analysis was performed
using Bodygram software version 1.2 (Akern).
Laboratory data were obtained in a central laboratory.
Blood glucose, t-CHO, HDL-CHO, LDL-CHO and triglyc-
erides, and HbA1c were measured by enzymatic methods
(Roche Molecular Biochemicals, Mannheim, Germany).
A two-site, solid-phase chemiluminescent immuno-
metric assay or competitive immunoassay (Immulite 2000
Analyzer; DPC, Los Angeles, CA) was used for C-peptide
with intra- and interassay coefficients of variation (CVs) of
1.9-3.3% and 3.8-5.5%, and PTH levels (CVs, 4.2-5.7% and
6.3-8.8%). Levels of 25(OH)D3 (CVs, 1.7-7.8 and 2.2-10.7%)
and insulin (CVs, 0.8-1.5% and 2.4-4.9%) were measured
using a Cobas Integra 800 Autoanalyzer (Roche Diagnostics,
Indianapolis, IN). Ultrasensitive C-reactive protein was
measured by (latex) HS Roche kit using Cobas Integra
800 (Roche Diagnostics).
Statistical analysis
Statistical analyses were performed using IBM SPSS
(version 18, Somers, NY, USA). The statistical significance
standard was set at 5%. Data normality was tested
using the Shapiro Wilk test. If data points were not
normally distributed, statistical analysis was attempted
on the natural logarithm of the values to improve the
symmetry and homoscedasticity of the distribution.
Log-transformed values of 25(OH)D3, PTH, glucose,insulin, c-peptide, C-reactive protein, HbA1c, calcium
and phosphorus were therefore used for comparative,
univariate and multivariate analyses. For homogeneity of
presentation, both normally distributed and non-normally
distributed data are presented as medians with interquartile
ranges (IQR). Differences in categorical variables were ana-
lyzed by χ2 test, and two-tailed, unpaired T- test or analysis
of covariance were used for continuous variables depending
on their distribution. Regression analyses and analysis
of variance for multiple dependent variables by one or
more factor variables or covariates were calculated
using the general linear model multivariate procedure,
comprising of the effects of covariate interactions with
the variables of interest. To determine the impact of
vitamin D status on metabolic variables, different models
were attempted and the following covariates of inter-
est, as well as their interaction, were used if not mutu-
ally excluded by the collinearity test: age, gender, BMI,
percent fat body mass, fat body mass in weight, lean
body mass in weight, and WHR. Multivariate linear
and logistic regression analysis were used to estimate
the coefficients of the linear equation, involving one or
more independent variables, that best predict the value
of the dependent variable.
Results
Data from 524 severely obese patients (303 females;
221 males), consecutively recruited according to the
inclusion criteria, constituted our analytical sample, as
detailed in Table 1. After subgrouping by gender, there
were expected differences in anthropometric and meta-
bolic parameters, whilst 25(OH)D3 and PTH levels were
not dissimilar between men and women. In the population
as a whole, screening for T2DM by the OGTT and HbA1c
levels revealed normal glucose metabolism in 37.8%, while
IFG / IGT were present in 40.5%; de novo T2DM was di-
agnosed in 21.7% of subjects (Table 2). Analysis of 25(OH)
D3 levels showed no seasonal variations, and 25(OH)D3
concentrations were in the range of deficiency in 84.7%
(N = 444; F/M, 57.4/42.6%), insufficiency in 10.3% (N = 54;
F/M, 58.2/41.8%) and normalcy in 5% of patients (N = 26;
F/M, 64.0/46.0%). The distribution of vitamin D status
was similar between genders. Although the prevalence
of glucose alterations differed markedly across categor-
ies of vitamin D status (Table 3), the only difference
achieving statistical significance was documented for
C-peptide levels. Of note, analysis of the lipid panel
underscored significant differences in HDL-CHO, LDL-
CHO and triglycerides levels in function of vitamin D
status (Table 3). When vitamin D status was analyzed in
function of glucose metabolism we could only observe
nonsignificant differences across groups after controlling
for age, BMI and gender (Table 4). Oppositely, when the
propensity toward vitamin D deficiency was analyzed in
Table 1 Anthropometric and analytical variables obtained in the study population
Parameters Whole population Males Females P
(N = 524) (N = 221) (N = 303)
Age (years) 52.0 [40.0-62.0] 47.0 [39.0-59.0] 54.0 [41.0-64.0] 0.001
BMI (kg/m2) 46.6 [43.1-50.9] 46.8 [42.6-51.2] 46.3 [43.3-50.8] 0.001
WHR 0.94 [0.89-1.0] 1.02 [0.98-1.08] 0.90 [0.85-0.93] 0.0001
Fat mass (%) 50.0 [44.1-54.3] 42.2 [38.3-46.0] 53.4 [50.3-56.2] 0.0001
C-reactive protein (mg/dl) 0.6 [0.4-1.1] 0.5 [0.3-1.9] 0.7 [0.4-1.2] 0.0001
FPG (mg/dl) 96.0 [90.0-107.0] 98.0 [90.0-110.5] 95.0 [89.0-105.0] 0.0002
Post-OGTT glucose (mg/dl) 143.0 [112.0-178.0] 157.0 [125.0-187.0] 135.0 [107.0-164.0] 0.0001
Fasting insulin (μU/ml) 13.1 [8.9-20.0] 15.5 [10.3-24.1] 12.3 [7.9-17.4] 0.001
Post-OGTT insulin (μU/ml) 89.0 [56.5-138.6] 102.3 [69.6-164.7] 77.4 [50.7-123.6] 0.0001
Fasting C-peptide (μg/l) 3.6 [2.8-4.6] 3.9 [3.2-5.0] 3.4 [2.7-4.3] 0.0001
HbA1c (%) 5.7 [5.5-6.0] 5.7 [5.5-6.1] 5.7 [5.5-6.0] 0.005
HOMA-IR 3.2 [2.0-4.9] 3.5 [2.3-5.9] 2.9 [1.9-4.2] 0.0002
25(OH)D3 (ng/ml) 10.3 [9.0-15.8] 10.8 [9.0-17.0] 10.0 [9.0-15.2] 0.98
PTH (pg/ml) 65.5 [48.2-90.4] 64.3 [48.0-91.8] 66.0 [48.5-89.5] 0.88
Phosphorus (mg/dl) 3.6 [3.3-4.0] 3.6 [3.2-4.0] 3.7 [3.3-4.1] 0.0005
Calcium (mg/dl) 9.1 [8.8-9.4] 9.1 [8.8-9.4] 9.1 [8.8-9.4] 0.93
Triglycerides (mg/dl) 131.0 [101.7-172.0] 142.0 [109.0-184.0] 126.0 [94.0-167.0] 0.0001
Total cholesterol (mg/dl) 218.0 [191.0-247.4] 188.0 [165.0-213.0] 193.0 [172.0-221.0] 0.11
LDL cholesterol (mg/dl) 144.0 [122.0-171.0] 120.0 [101.0-145.0] 123.0 [104.0-144.0] 0.78
HDL cholesterol (mg/dl) 50.0 [42.0-62.0] 37.0 [31.0-43.0] 45.0 [38.0-57.0] 0.0001
Patients with NGT (%) 37.8 26.2 46.2 0.0001
Patients with IFG-IGT (%) 40.5 45.2 37.0 0.05
Patients with T2DM (%) 21.7 28.5 16.8 0.001
Data are presented as median values and interquartile ranges. For comparative analysis between genders, significance is calculated by unpaired T test for age
and BMI, and by analysis of covariance for all other variables with age and BMI as covariates. The χ2 test was used for comparative analyses between patients with NGT,
IFG + IGT and T2DM. For abbreviations: BMI, Body Mass Index; WHR, Waist-to-Hip Ratio; FPG, Fasting Plasma Glucose; HbA1c, Glycated Haemoglobin; HOMA-IR,
Homeostatic Model of Insulin Resistance; 25(OH)D3, 25-hydroxy-vitamin D; PTH, Parathyroid Hormone; NGT, Normal Glucose Tolerance; IFG, Impaired Fasting
Glucose; IGT, Impaired Glucose Tolerance; T2DM, Type 2 Diabetes Mellitus.
Bellan et al. Cardiovascular Diabetology 2014, 13:57 Page 4 of 10
http://www.cardiab.com/content/13/1/57function of glucose metabolism controlled for age, BMI
and gender, we found that the prevalence of vitamin D
deficiency was slightly but significantly greater (87% vs.
80%; OR: 1.75, 95% CI: 1.03-2.99; p = 0.04) in patients
with an abnormal glucose profile (IFG + IGT + T2DM)
compared to those with normal tolerance.Table 2 Patients distribution according to vitamin D
status and glucose homeostasis
25(OH)D3
deficiency
25(OH)D3
insufficiency
25(OH)D3
adequacy
Total
NGT 160 (30.5%) 28 (51.8%) 10 (38.5%) 198 (37.8%)
IFG/IGT 184 (35.1%) 17 (31.5%) 11 (42.3%) 212 (40.5%)
T2DM 100 (19.1%) 9 (16.7%) 5 (19.2%) 114 (21.7%)
Total 444 (84.7%) 54 (10.3%) 26 (5.0%) 524 (100%)
Data are presented as cumulative values with percentages in parentheses. For
abbreviations: 25(OH)D3, 25-hydroxyvitamin D; PTH, Parathyroid Hormone;
NGT, Normal Glucose Tolerance; IFG, Impaired Fasting Glucose; IGT, Impaired
Glucose Tolerance; T2DM, Type 2 Diabetes Mellitus.Analysis of PTH levels revealed secondary hyperpara-
thyroidism (PTH ≥65 pg/ml) in 50.8% of obese patients as
a whole, and 54.7% of those with vitamin D deficiency/
insufficiency. Having vitamin D levels in the range of
deficiency (<20 ng/ml) significantly increased the risk
of secondary hyperparathyroidism (O.R., 2.38; 95% CI,
1.38-4.1; p < 0.01). PTH concentrations tended to increase
proportionately to abnormalities of glucose metabolism
(Table 4).
Correlation analysis was carried out after adjusting for
age, BMI, and gender (Figure 1). We found no correlation
between 25(OH)D3 and either baseline or post-OGTT
glucose levels, while HbA1c levels increased progressively
with declining 25(OH)D3 levels (r = −0.091, p = 0.04).
Of note, 25(OH)D3 concentrations were related to insulin
levels by direct association, both in fasting conditions
(r = 0.097, p = 0.03) and after OGTT (r = 0.099, p = 0.02),
with near-significant associations to HOMA-IR (r = 0.085,
p = 0.053) and c-peptide levels (r = 0.084, p = 0.06). A
Table 3 Differences in continuous variables according to vitamin D status
25(OH)D3 deficiency 25(OH)D3 insufficiency 25(OH)D3 adequacy p
(N = 444) (N = 55) (N = 25)
Age (years) 53.0 [40.0-61.0] 52.5 [38.7-64.0] 52.0 [46.2-68.0] 0.78
BMI (kg/m2) 46.7 [43.3-51.3] 46.4 [41.2-49.0] 43.4 [40.8-47.1] 0.01
WHR 0.94 [0.89-1.02] 0.93 [0.88-1.01] 0.97 [0.90-1.03] 0.33
Fat mass (%) 49.6 [44.3-54.5] 50.0 [41.9-53.9] 51.0 [41.8-53.5] 0.59
C-reactive protein (mg/dl) 0.6 [0.4-1.1] 0.5 [0.3-1.0] 0.5 [0.4-1.0] 0.59
FPG (mg/dl) 96.0 [90.0-107.0] 93.0 [86.7-101.2] 97.0 [91.5-111.2] 0.06
Post-OGTT glucose (mg/dl) 144.0 [113.0-178.0] 125.0 [104.5-171.0] 136.0 [97.5-185.5] 0.29
Fasting insulin (μU/ml) 12.9 [8.6-19.8] 15.3 [10.0-20.9] 12.8 [8.6-25.4] 0.08
Post-OGTT insulin (μU/ml) 89.9 [55.1-138.8] 81.0 [57.4-135.6] 78.2 [52.9-135.0] 0.91
Fasting C-peptide (μg/l) 3.6 [2.8-4.6] 3.2 [2.5-4.9] 4.0 [3.0-5.9] 0.04
HbA1c (%) 5.8 [5.5-6.1] 5.6 [5.4-5.9] 5.7 [5.4-6.0] 0.10
HOMA-IR 3.1 [2.0-5.0] 3.6 [2.2-4.8] 3.3 [1.9-5.3] 0.14
PTH (pg/ml) 67.7 [50.0-93.2] 52.4 [39.6-70.8] 60.2 [34.2-74.2] 0.002
Phosphorus (mg/dl) 3.6 [3.3-4.0] 3.6 [3.1-3.8] 3.7 [3.5-4.1] 0.44
Calcium (mg/dl) 9.1 [8.8-9.4] 9.2 [8.9-9.5] 9.3 [9.0-9.5] 0.20
Triglycerides (mg/dl) 133.0 [102.0-174.2] 122.5 [91.0-155.0] 130.0 [101.0-168.0] 0.02
Total cholesterol (mg/dl) 192.0 [169.0-218.2] 182.0 [165.5-205.7] 200.0 [167.7-233.5] 0.09
LDL cholesterol (mg/dl) 122.0 [102.0-144.0] 110.5 [91.2-139.7] 126.0 [104.0-151.2] 0.04
HDL cholesterol (mg/dl) 41.5 [34.0-49.2] 46.5 [38.0-56.2] 41.5 [33.2-55.7] 0.04
Data are presented as median values and interquartile ranges. For comparative analysis, significance is calculated by ANOVA for age and BMI, and by analysis of
covariance for all other variables using age, BMI and gender as covariates. Categories of Vitamin D status are detailed in the Patients and Methods section. For
abbreviations: BMI, Body Mass Index; WHR, Waist-to-Hip Ratio; FPG, Fasting Plasma Glucose; HbA1c, Glycated Haemoglobin; HOMA-IR, Homeostatic Model of Insulin
Resistance; 25(OH)D3, 25-hydroxy-vitamin D; PTH, Parathyroid Hormone; NGT, Normal Glucose Tolerance; IFG, Impaired Fasting Glucose; IGT, Impaired Glucose
Tolerance; T2DM, Type 2 Diabetes Mellitus.
Table 4 Difference in continuous variables between
patients aggregated by glucose homeostasis
NPG + NGT IFG + IGT + T2DM P
(N = 198) (N = 326)
Age (years) 45.0 [33.0- 58.2] 55.0 [44.0-62.7] 0.001
BMI (kg/m2) 46.3 [43.3-50.0] 46.7 [43.0-51.1] 0.91
WHR 0.91 [0.86-1.00] 0.97 [0.90-1.04] 0.13
Fat mass (%) 51.0 [47.9-54.8] 48.3 [42.2-54.0] 0.18
C-reactive protein (mg/dl) 0.6 [0.4-1.1] 0.6 [0.3-1.1] 0.56
25(OH)D3 (ng/ml) 11.0 [9.0-17.6] 9.9 [9.0-15.0] 0.23
PTH (pg/ml) 62.6 [45.9-85.0] 67.7 [50.2-96.1] 0.22
Phosphorus (mg/dl) 3.7 [3.4-4.0] 3.6 [3.2-4.0] 0.95
Calcium (mg/dl) 9.1 [8.8-9.4] 9.1 [8.8-9.4] 0.80
Data are presented as median values and interquartile ranges. For
comparative analysis, significance is calculated by ANOVA for age and BMI,
and by analysis of covariance for all other variables using age, BMI and gender
as covariates. For abbreviations: NPG, Normal Plasma Glucose; NGT, Normal
Glucose Tolerance; IFG, Impaired Fasting Glucose; IGT, Impaired Glucose
Tolerance; T2DM, Type 2 Diabetes Mellitus; BMI, Body Mass Index; WHR,
Waist-to-Hip Ratio; 25(OH)D3, 25-hydroxy-vitamin D; PTH, Parathyroid
Hormone; CRP, C-reactive protein.
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HDL-CHO levels (r = 0.13, p = 0.002). In addition to the
previous, 25(OH)D3 concentrations were markedly cor-
related to PTH (r = −0.27, p < 0.0001) and calcium levels
(r = 0.13, p = 0.002).
Multiple logistic regression analysis was conducted on
patients grouped by their glucose homeostasis as toler-
ant (NPG + NGT) and intolerant (IFG + IGT + T2DM).
A correct vitamin D status was found to reduce the
risk of glucose alterations (OR: 0.59; 95% CI: 0.36-1.00;
p < 0.05), although aging (OR: 1.04; 95% CI: 1.02-1.05;
p < 0.0001) and female gender (OR: 0.33; 95% CI: 0.22-
0.50; p < 0.0001) played a more dominant role on such
event. However, the effect of vitamin D was lost upon
inclusion of BMI in the regression equation.
In stepwise multivariate regression analysis, vitamin
D levels showed the ability to predict HbA1c levels
(β = −0.101, p = 0.026) after age (β =0.213, p = 0.001) and
WHR (β = 0.207, p = 0.001). Neither BMI nor gender
entered the regression equation. Vitamin D did not elicit
any predictive effect on the remaining indices of glucose
metabolism. When PTH replaced vitamin D levels as a
continuous variable in analysis of covariance and in linear
Figure 1 Univariate regression analysis between metabolic variables of interest and vitamin D levels. Individual data represent
continuous variables. Regression coefficients were calculated by the general linear model on individual log-transformed values after controlling
for age, BMI and gender. For abbreviations: 25(OH)D3, 25-hydroxyvitamin D; HbA1c, Glycated Haemoglobin; PTH, Parathyroid Hormone; OGTT, Oral
Glucose Tolerance Test; HDL-CHO, HDL Cholesterol.
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significant effect of PTH levels on glucose and lipid me-
tabolism after controlling for key covariates used through-
out the data analysis procedures.
Discussion
This study, undertaken to assess if a causal relationship
links glucose homeostasis and naive T2DM to vitamin Dstatus in obesity, documented a negative effect of vitamin D
deficiency on glycated haemoglobin when the effect of age,
BMI, and gender was accounted for. Our analysis did
not capture a direct association between diabetes mellitus
and vitamin D, possibly due to the overwhelming effects
of obesity on both conditions, however patients with im-
paired glucose tolerance clustered more frequently with
an altered vitamin D status, after controlling for potential
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vitamin D to metabolic homeostasis in obesity was substan-
tiated by the observed association between vitamin D and
insulin secretion, as well as HDL cholesterol levels.
Evidence collected until now shows that the relation-
ship between T2DM and hypovitaminosis D is debatable,
as the bulk of data is based on observational or epi-
demiological studies, which are useful for generating hy-
potheses but not for proving causality [31]. In previous
studies, lower vitamin D concentrations were independ-
ently associated with obesity, metabolic syndrome and
IFG in a teenager population, with the risk of IFG being
doubled in patients at the lowest compared to those at
the highest quartile of vitamin D [32]. Similarly, waist
circumference, triglycerides, fasting glucose and insulin
sensitivity impairment were predicted by low vitamin D
levels in an adult cohort of Australian patients [33]. Data
from adults showed that hypovitaminosis D is correlated
with the development of IGT [34], and an inverse correl-
ation has been described between vitamin D concentrations
and the risk of developing T2DM in a 22-year follow-up
Finnish cohort study [35]; in obstructive sleep apnea
syndrome-patients, vitamin D concentrations have also
been inversely related to the risk of diabetes and metabolic
syndrome [36]. Likewise, a higher prevalence of hypovita-
minosis D was reported in diabetic patients compared to
healthy controls in a population of middle aged Caucasian
men and women and in South Asian UK residents [37,38].
Prospective studies prompted an inverse association
between 25(OH)D3 levels and future glycemia and in-
sulin resistance [39]. Finally, vitamin D seems to play a
protective role on macrovascular damage in murine models
of diabetes, slowing down one of the main diabetes related
complications [40].
To the best of our knowledge, this is the first large
study investigating such relationship in a homogeneous
subset of severely obese patients, subjected to screening
for T2DM by different biochemical approaches. One main
finding consisted in the observation that neither 25(OH)
D3 concentrations were lower nor hypovitaminosis D
was significantly more frequent in prediabetic and dia-
betic obese patients compared to those with normogly-
caemia, likely due to the blunting effect of obesity on
circulating vitamin D levels. At variance with previous
reports [32,34], we were unable to disclose negative effects
of low 25(OH)D3 concentrations on plasma glucose levels
both in fasting conditions and after the oral glucose
challenge after correction for multiple variables known
to affect glucose metabolism. Even so, we confirm the
inverse correlation between 25(OH)D3 and glycated
haemoglobin, an established marker of glucose homeostasis
[30,41,42]. It would be therefore important to expand to
obesity results of prospective cohort studies describing an
inverse association between vitamin D levels and the oddsof transitioning from normoglycaemia to IFG, from
normoglycaemia to T2DM and from IFG to T2DM [43],
confirmed by a recent meta-analysis [44]. Another cir-
cumstance suggestive of this association involves the
direct correlation found between 25(OH)D3 and insulin
levels, both on fasting and after the OGTT. In previous
studies on individuals at risk for T2DM [45], 25(OH)D3
concentrations were independently associated to insulin
sensitivity and beta-cell function, and in subjects at risk or
not for T2DM a positive correlation was found between
vitamin D and early response of C-peptide and insulin
levels to the oral glucose challenge [46]. Our findings may
thus support the notion that vitamin D yields regulatory
effects on insulin secretion in vitro and in vivo [47-49],
while being in apparent contrast with previous inconclu-
sive studies on poorly-controlled T2DM-patients with
exhausted insulin secretion [50]. Because our patients
harboured a glucose tolerance that spanned from normal
to naive T2DM, and may have thus retained a superior
beta-cell activity than patients with chronic T2DM, our
results support the findings of Harris et al., who studied
the effects of vitamin D supplementation in prediabetic
obese patients and showed that the increase in 25(OH)D3
concentrations was associated with an increase of insulin
secretion rate and C-peptide concentrations [51]. In a
study by Guasch et al. [52], high 25(OH)D3 levels were
significantly associated with HDL-cholesterol levels
and diabetes/hyperglycemia, but this relationship was
lost after adjustment for BMI. Also, vitamin D supple-
mentation was shown to improve the metabolic profile of
diabetic Saudi individuals undergoing different therapeutic
regimens, with particular effectiveness on HDL-cholesterol
levels [53]. In our analysis, the lipid profile clearly reflected
vitamin D status, and high 25(OH)D3 levels were signifi-
cantly associated with higher levels of HDL cholesterol,
after adjustment for key confounding factors. This seems
to confirm that vitamin D status is inversely related to
atherogenic dyslipidemia [54,55], and indirectly suggests
that vitamin D may be independently protective against
the atherogenic profile in a population at high risk for
cardiovascular disease.
Finally, current results substantiate the known high
prevalence of vitamin D deficiency associated with obesity;
the reason for this association has not been fully defined,
and is commonly attributed to vitamin D accumulation in
the adipose tissue [22,56-61]. In our experience, the cumu-
lative prevalence of vitamin D deficiency and insufficiency
was 95%. In our clinical practice, patients diagnosed
with vitamin D deficiency receive cholecalciferol treatment
(300.000 units p.o. for two consecutive days) and undergo
regular follow-up. Also frequent was secondary hyperpara-
thyroidism, affecting nearly 55% of subjects with vitamin D
deficiency/insufficiency. These figures consolidate those
found in similar studies [62,63]. Peculiarly, we observed
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levels on one hand, and calcium concentrations on the
other, both confirming the secondary origin of hyper-
parathyroidism. In multivariate analysis, the enhancing
effect of hypovitaminosis D on PTH secretion was inde-
pendent of common confounding factors herein associ-
ated. It is important to note that growing attention has
recently focused on PTH as being a potentially closer
factor associated to metabolic abnormalities than vita-
min D levels. PTH plays a role in increasing the cardio-
vascular risk possibly via its effects on blood pressure,
insulin resistance, hyperglycaemia and low HDL-CHO
levels [64]. In a population-based cross-sectional study
of US men and women, the odds ratio for metabolic
syndrome increased with increasing PTH in older men
only [64], while a survey in aging European population
showed that a decreased risk for metabolic syndrome
with increasing quintiles of 25(OH)D3 but not with PTH
[65]. Neither of these studies was adjusted for BMI. In
another study in obese subjects, PTH was paradigmatically
associated to the metabolic syndrome via other biomarkers
like vitamin D and magnesium, albeit this association
was only significant in women [66]. Based on our analysis
in severely obese patients, our results do not appear to con-
firm the predictive role of PTH on metabolic derangement
when BMI, age and gender are accounted for. It would be
valuable to corroborate this observation in a study encom-
passing a wider BMI range.
The cross-sectional design of our study represents its
main limitation, since no cause-effect relationship could
have been investigated. Further studies are required to
better define the impact of vitamin D status on the devel-
opment of glucose metabolism alterations. Furthermore
we have no data on the effect of vitamin D supplementa-
tion on glycated haemoglobin. Recently, the correction of
poor vitamin D status has been inversely associated with
fasting insulin and HOMA-IR, in obese adolescents, but
the effect on HbA1c levels has not been investigated [67].
An interventional study should specifically address this
issue. Finally, if, on one hand, the high homogeneity of
our sample could be considered a strength, on the other
hand it could be seen as a weakness, since the selection of
severely obese patients could have masked the relationship
between vitamin D status and glucose metabolism. Some
of the strengths of this study should not be neglected, in-
cluding the significant amount of clinical data collected in
a large population of obese people, the status of previously
undiagnosed glucose abnormalities, and the adjustment
for common confounders such as age, BMI, and gender.
Conclusions
While confirming the high prevalence of hypovitaminosis
D in severe obesity, current data suggest a possible role
for vitamin D in the regulation of glucose tolerance, insulinsecretion and lipid metabolism, on which obesity plays
per se a dominant effect. Indirectly, our findings support
the importance of vitamin D in contributing to metabolic
homeostasis in obesity.
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